Is the Venner-PneuX Endotracheal Tube System a Cost-Effective Option for Post Cardiac Surgery Care?

Andronis, Lazaros; Oppong, Raymond; Manga, Na'ngono; Senanayake, Eshan; Gopal, Shameer; Charman, Susan C.; Giri, Ramesh; Luckraz, Heyman

doi:10.1016/j.athoracsur.2018.03.058

Cited by 5 publications

(6 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We assume 0.01126 QALYs lost per admission and 0.274 HRQoL loss for 15 days, based on people in hospital for pneumonia [ 24 ]. Cost per admission of £7,085 is (NHS Wales Finance Delivery Unit).…”

Section: Methodsmentioning

confidence: 99%

“…We assume 0.01126 QALYs lost per admission and 0.274 HRQoL loss for 15 days, based on people in hospital for pneumonia. 27 Cost per admission of £7,085 is (NHS Wales Finance Delivery Unit). We assume 1.402 HRQoL loss for 9 days 27 (Note this means that the QALYs for this health state are ‘worse than death’).…”

Section: Methodsmentioning

confidence: 99%

“…27 Cost per admission of £7,085 is (NHS Wales Finance Delivery Unit). We assume 1.402 HRQoL loss for 9 days 27 (Note this means that the QALYs for this health state are ‘worse than death’). Cost per admission is £22,198 (NHS Wales Finance Delivery Unit).…”

Section: Methodsmentioning

confidence: 99%

See 2 more Smart Citations

Cost-effectiveness of a whole-area testing pilot of asymptomatic SARS-CoV-2 infections with lateral flow devices: A modelling and economic analysis study

Drakesmith

Collins

Nnoaham

et al. 2021

Preprint

View full text Add to dashboard Cite

Objectives: To evaluate the cost effectiveness of an asymptomatic SARS-CoV-2 whole area testing pilot. Design: Epidemiological modelling and cost effectiveness analysis. Setting: The community of Merthyr Tydfil County Borough between20 Nov and 21 Dec 2020. Participants: A total of 33,822 people tested as part of the pilot in Merthyr Tydfil County Borough, 712 of whom tested positive by lateral flow test and reported being asymptomatic. Main outcome measures: Estimated number of cases, hospitalisations, ICU admissions and deaths prevented, and associated costs per quality-adjusted life years (QALYs) gained and monitory cost to the healthcare system. Results: An initial conservative estimate of 360 (95% CI: 311 - 418) cases were prevented by the mass testing, representing a would-be reduction of 11% of all cases diagnosed in Merthyr Tydfil residents during the same period. Modelling healthcare burden estimates that 24 (16 - 36) hospitalizations, 5 (3 - 6) ICU admissions and 15 (11 - 20) deaths were prevented, representing 6.37%, 11.1% and 8.19%, respectively of the actual counts during the same period. A less conservative, best-case scenario predicts a much higher number of cases prevented of 2328 (1761 - 3107), representing 80% reduction in would-be cases. Cost effectiveness analysis indicates 108 (80 - 143) QALYs gained, an incremental cost ratio of &#163 2,143 (&#163 860-&#163 4,175) per QALY gained and net monetary benefit of &#163 6.2m (&#163 4.5m-&#163 8.4m). In the less conservative scenario, the net monetary benefit increases to &#163 15.9m (&#163 12.3m-&#163 20.5m). Conclusions: A significant number of cases, hospitalisations and deaths were prevented by the mass testing pilot. Considering QALYs lost and healthcare costs avoided, the pilot was cost-effective. These findings suggest mass testing with LFDs in areas of high prevalence (>2%) is likely to provide significant public health benefit. It is not yet clear whether similar benefits will be obtained in low prevalence settings.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Cost-effectiveness of a whole-area testing pilot of asymptomatic SARS-CoV-2 infections with lateral flow devices: A modelling and economic analysis study

Drakesmith

Collins

Nnoaham

et al. 2021

Preprint

View full text Add to dashboard Cite

show abstract

“…We assume 0.01126 QALYs lost per admission and 0.274 HRQoL loss for 15 days, based on people in hospital for pneumonia [30]. Cost per admission of £7,085 is (NHS Wales Finance Delivery Unit).…”

Section: Hospital and Icu Admissionsmentioning

confidence: 99%

“…Cost per admission of £7,085 is (NHS Wales Finance Delivery Unit). We assume 1.402 HRQoL loss for 9 days [30] (Note this means that the QALYs for this health state are 'worse than death'). Cost per ICU admission is £22,198 (NHS Wales Finance Delivery Unit).…”

Section: Hospital and Icu Admissionsmentioning

confidence: 99%

Cost-effectiveness of a whole-area testing pilot of asymptomatic SARS-CoV-2 infections with lateral flow devices: a modelling and economic analysis study

Drakesmith

Collins

Jones

et al. 2022

BMC Health Serv Res

View full text Add to dashboard Cite

Background Mass community testing for SARS-CoV-2 by lateral flow devices (LFDs) aims to reduce prevalence in the community. However its effectiveness as a public heath intervention is disputed. Method Data from a mass testing pilot in the Borough of Merthyr Tydfil in late 2020 was used to model cases, hospitalisations, ICU admissions and deaths prevented. Further economic analysis with a healthcare perspective assessed cost-effectiveness in terms of healthcare costs avoided and QALYs gained. Results An initial conservative estimate of 360 (95% CI: 311–418) cases were prevented by the mass testing, representing a would-be reduction of 11% of all cases diagnosed in Merthyr Tydfil residents during the same period. Modelling healthcare burden estimates that 24 (16—36) hospitalizations, 5 (3–6) ICU admissions and 15 (11–20) deaths were prevented, representing 6.37%, 11.1% and 8.2%, respectively of the actual counts during the same period. A less conservative, best-case scenario predicts 2333 (1764–3115) cases prevented, representing 80% reduction in would-be cases. Cost -effectiveness analysis indicates 108 (80–143) QALYs gained, an incremental cost-effectiveness ratio of £2,143 (£860-£4,175) per QALY gained and net monetary benefit of £6.2 m (£4.5 m-£8.4 m). In the best-case scenario, this increases to £15.9 m (£12.3 m-£20.5 m). Conclusions A non-negligible number of cases, hospitalisations and deaths were prevented by the mass testing pilot. Considering QALYs gained and healthcare costs avoided, the pilot was cost-effective. These findings suggest mass testing with LFDs in areas of high prevalence (> 2%) is likely to provide significant public health benefit. It is not yet clear whether similar benefits will be obtained in low prevalence settings or with vaccination rollout.

show abstract

Review of health economic models exploring and evaluating treatment and management of hospital-acquired pneumonia and ventilator-associated pneumonia

Wagner

Enne

Livermore

et al. 2020

Journal of Hospital Infection

View full text Add to dashboard Cite

Is the Venner-PneuX Endotracheal Tube System a Cost-Effective Option for Post Cardiac Surgery Care?

Abstract: VPX resulted in improved outcomes and savings that far offset the cost of the device, suggesting that replacing SET with VPX is overall beneficial. Findings were robust to extreme values of key variables.

Cited by 5 publications

References 23 publications

Cost-effectiveness of a whole-area testing pilot of asymptomatic SARS-CoV-2 infections with lateral flow devices: A modelling and economic analysis study

Cost-effectiveness of a whole-area testing pilot of asymptomatic SARS-CoV-2 infections with lateral flow devices: A modelling and economic analysis study

Cost-effectiveness of a whole-area testing pilot of asymptomatic SARS-CoV-2 infections with lateral flow devices: a modelling and economic analysis study

Review of health economic models exploring and evaluating treatment and management of hospital-acquired pneumonia and ventilator-associated pneumonia

Contact Info

Product

Resources

About